Some Aspects of Dihydropyridine Calcium Antagonists USE in the Treatment of Hypertension Part 2

A.D. Radchenko


This article is the second part of the review of the literature on the use of calcium antagonists in the treatment of hypertension. There were considered the questions on the efficacy of dihydropyridine calcium antagonists in various categories of patients and possibilities of their combination with other classes of antihypertensive and non-antihypertensive drugs.


hypertension; complications; calcium antagonists; drug use safety


Барна О., Лапшин О. Труднощі в лікуванні артеріальної гіпертензії: які питання може вирішити лерканідипін? // Ліки України. — 2012. — № 8. — С. 28-32.

Мелина И. Гипертоническая болезнь у беременных [Текст] / А.Г. Коломийцева [и др.]. — К.: Здоров’я, 1988. — 191 с.

Савенков М.П., Іванов С.Н., Иванова С.В., Соломонова Л.А. и др. Варианты применения фиксированной комбинации лизиноприла и амлодипина при лечении артериальной гипертонии // РМЖ. — 2010. — Т. 18, № 3. — С. 106-108.

Сиренко Ю. Когда возможности используются недостаточно, или Как убедить врача назначать статины? // Український медичний часопис. — 2009. — № 2. — Доступно

Робоча група з артеріальної гіпертензії Української Асоціації кардіологів. Артеріальна гіпертензія. Оновлена та адаптована клінічна настанова, заснована на доказах. — К., 2012. — 108 с.

2007 European Society of Hypertension — European Society of Cardiology guidelines for management of arterial hypertension //

J. Hypertension. — 2007. — Vol. 25. — P. 1105-1187.

2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. — 2013. — Vol. 31. — P. 1281-1357.

Amery A., Birkenhager W., Brixko P., Bulpitt C., Clement D., Deruyttere M., De Schaepdryver A., Dollery C., Fagard R., Forette F. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial // Lancet. — 1985. — Vol. 1. — P. 1349-1354.

Aronow W., Fleg J., Pepine C. et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Developed in Collaboration With the Clinical Expert Consensus Documents American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension // J. Am. Coll. Cardiol. — 2011. — Vol. 57. — P. 2037-2114.

Athyros V.G., Mikhailidis D.P., Papageorgiou A.A. et al. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study // Curr. Med. Res. Opin. — 2004. — Vol. 20(9). — P. 1385-1392.

Baba S., J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics // Diabetes Res. Clin. Pract. — 2001. — Vol. 54(3). — P. 191-201.

Bakris G., Sarafidis P., Weir M. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial // The Lancet. — 2010. — Vol. 375. — P. 1173-1181.

Bakris G.L., Williams M., Dworkin L. et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Exe-

cutive Committees Working Group // Am. J. Kidney Dis. — 2000. — Vol. 36(3). — P. 646-661.

Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis // Am. J. Med. — 2007. — Vol. 120(8). — P. 713-719.

Barrios V., Calderon A., Navarro A. et al. Lercanidipine effectiveness and tolerability profile is not influenced by over weight or body fat increase. The LERZAMIG study // J. Hypertens. — 2004. — Vol. 22(Suppl. 2). — P. 258-9.

Barrios V., Calderon A., Navarro A. et al. Lercanidipine is an effective and well tolerated drug in essential hypertension, independently of the cardiovascular risk. The Laura study // J. Hypertens. — 2004. — Vol. 22, Suppl. 2. — S235.

Barrios V., Navarro A., Esteras A. et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad // Blood Press. — 2002. — Vol. 11. — P. 95-100.

Beckett N., Peters R., Fletcher A. et al. Treatment of Hypertension in Patients 80 Years of Age or Older // N. Engl. J. Med. — 2008. — Vol. 358. — P. 1887-1898.

Bellinghieri G., Mazzaglia G., Savica V., Santoro D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: A multicenter randomized controlled trial // Ren. Fail. — 2003. — Vol. 25. — P. 681-689.

Black H.R., Elliott W.J., Grandits G. et al. CONVINCE Trial group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial // JAMA. — 2003. — Vol. 289. — P. 2073-2082.

Blank R., LaSalle J., Reeves R. et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study) // J. Clin. Hypertens (Greenwich). — 2005. — Vol. 7(5). — P. 264-273.

Borhani N., Mercuri M., Borhani P. еt al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial // JAMA. — 1996. — Vol. 276. — P. 785-791.

Brown M.J., Castaigne A., Ruilope L.M. et al. ІNSIGHT: international nifedipine GITS study intervention as a goal in hypertension treatment // J. Hum. Hypertens. — 1996 Sep. — 10 (Suppl. 3). — S157-60.

Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) // Lancet. — 2000. — Vol. 356. — P. 366-372.

Cannon C.P., Braunwald E., McCabe C.H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes // N. Engl. J. Med. — 2004. — Vol. 350(15). — P. 1495-1504.

Chapman R.H., Benner J.S., Petrilla A.A. et al. Predictors of adherence with antihypertensive and lipid-lowering therapy // Arch. Intern. Med. — 2005. — Vol. 165(10). — P. 1147-1152.

Chobanian A., Bakris G., Black H. еt al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure // Hypertens. — 2003. —

Vol. 42. — P. 1206-1252.

Chung M., Calcagni A., Glue P., Bramson C. Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet //

J. Clin. Pharmacol. — 2006. — Vol. 46(9). — P. 1030-1037.

Chung M., Calcagni A., Glue P., Bramson C. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet // J. Clin. Pharmacol. — 2006. — Vol. 46(10). —

P. 1212-1216.

Cohn J., Neutel J., Houston M. et al. Early improvements in vascular compliance following coadministration of amlodipine and atorvastatin in patients with concomitant hypertension and dyslipi-demia. The Avalon Arterial Wall Compliance (AWC) trial. — San Francisco, CA: Program and abstracts from the 20th Annual Scientifc Meeting of the American Society of Hypertension, May 14–18, 2005.

Cohn J.N., Ziesche S., Smith R. et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-Heft III // Circulation. — 1997. — Vol. 96. — P. 856-863.

Colhoun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial // Lancet. — 2004. — Vol. 364(9435). — P. 685-696.

Csaba F., Gyorgy A., Peter K. et al. Amlodipin Lisinopril Fix-combination in patients with essential hypertension (ALFESS study) // Hypertension and Neurology. — 2009. — Vol. 13, № 2. — P. 81-88.

Cutler J.A. The ANBP2 and ALLHAT: Conflicting or consistent? // J. Clin. Hypertens. — 2003. — Vol. 5. — P. 192-195.

Dahlöf B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

Dahlöf B., Hansson L., Lindholm L. et al. STOP-Hypertension: Swedish Trial in Old Patients with Hypertension // Journal of Hypertension. — 1986. — Vol. 4. — P. 511-513.

Dalla Vestra M., Pozza G., Mosca A. et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL Study (diabete, ipertensione, albuminuria, lercanidipina) // Diab. Nutr. Metab. — 2004. — Vol. 17. — P. 259-266.

Del Vecchio L., Pozzi M., Salvetti A. et al. Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril // J. Nephrol. — 2004. — Vol. 17. — P. 261-269.

Díez J. Calcium channel blockers and renal dysfunction in arterial hypertension // Nephrol. Dial. Transplant. — 1995. — Vol. 10, Suppl. 6. — P. 22-26.

ENCORE investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function) // Circulation. — 2003. — Vol. 107. — P. 422-428.

Epstein M. Calcium Antagonists in Clinical Medicine. — Philadelphia: Hanley & Belfus, 2002. — 852 p.

Erdine S., Ro Y.M., Tse H.F. et al. Gemini-AALA Investigators. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study) // J. Hum. Hypertens. — 2009. — Vol. 23(3). — P. 196-210.

Estacio R., Jeffers B., Hiatt W. et al. The effect of nisoldipine as compared with enelapril on cardiovascular outcomes in patients with non insulin dependent diabetes and hypertension // N. Engl. J. Med. — 1998. — Vol. 338. — P. 645-652.

EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events // Lancet. — 2001. — Vol. 35. — P. 995-1001.

Farsang C. A HAMLET Vizsgalok neveben // Hypertonia es nephrologia. — 2004. — Vol. 8(2). — P. 72-78.

Flack J.M., Victor R., Watson K. et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial // Mayo Clin. Proc. — 2008. — Vol. 83(1). — P. 35-45.

Fogari R., Derosa G., Lazzari P. et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance // Am. J. Hypertens. — 2004. — Vol. 17(9). — P. 823-827.

Fogari R., Mugellini A., Zoppi A. et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria // Eur. J. Clin. Pharmacol. — 2005. — Vol. 61. — P. 483-490.

Fogari R., Preti P., Zoppi A. et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients // Eur. J. Clin. Pharmacol. — 2006. — Vol. 62(10). — P. 817-822.

Go A., Mozaffarian D., Roger V. et al. Оn behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics — 2013 Update: A Report From the American Heart Association // Circulation. — 2013. — Vol. 127. — P. 6-245.

Gu Q., Burt V.L., Dillon C.F., Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010 // Circulation. — 2012. — Vol. 126. — P. 2105-2114.

Hobbs F.D.R., Gensini G., Mancini G.B.J. et al. For the

JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme // Eur. J. Cardiovasc Prev. Rehabil. — 2009. — Vol. 16. — P. 472-480.

Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension // JAMA. — 1979. — Vol. 242. — P. 2562-2571.

Insull W. The problem of compliance to cholesterol altering therapy // J. Intern. Med. — 1997. — Vol. 241. — P. 317-325.

Izzo J., Levy D., Black H.R. Importance of systolic blood pressure in older Americans // Hypertension. — 2000. — Vol. 35. — P. 1021-1024.

Jamerson K.A. Оn behalf of the ACCOMPLISH investigators. Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension // American College of Cardiology Scientific Sessions. — March 31, 2008; Chicago, IL.

Jukema J.W., Zwinderman A.H., van Boven A.J., Reiber J.H.C. et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels // Arterioscler. Thromb. Vasc. Biol. — 1996. — Vol. 16. — P. 425-430.

Corrao G., Nicotra F., Parodi A. et al. Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice // Hypertension. — 2011. — Vol. 58. — P. 566-572.

Julius S., Cohn J.N., Neutel J. et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial // J. Clin. Hypertens. — 2004. — Vol. 6. — P. 10-17.

Julius S., Kjeldsen S.E., Weber M. et al. VALUE trial group. Outcomes inhypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. — 2004. — Vol. 363. — P. 2022-2031.

Koren M.J., Hunninghake D.B. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study //

J. Am. Coll. Cardiol. — 2004. — Vol. 44(9). — P. 1772-1779.

Krause T., Lovibond K., Caulfield M. et al. Management of hypertension: summary of NICE guidance // BMJ. — 2011. — Vol. 343. — P. 1-6 (d4891 doi: 10.1136/bmj.d4891).

LaRosa J.C., Grundy S.M., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease // N. Engl. J. Med. — 2005. — Vol. 352(14). — P. 1425-1435.

Leibovitz E., Beniashvili M., Zimlichman R., Freiman A., Shargorodsky M., Gavish D. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients // Am. J. Hypertens. — 2003. — Vol. 16 (9, Pt. 1). — P. 715-718.

Lichtlen P.R., Hugenholtz P.G., Rafflenbeul W. et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators // Lancet. — 1990. — Vol. 335. — P. 1109-1113.

Lindgren P., Buxton M., Kahan T. et al. Amlodipine + atorvastatin is cost effective compared to atenolol + atorvastatin, amlodipine or atorvastatin alone: the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) // Eur. Heart J. — 2007. — Vol. 28

(Abstr. Suppl.). — P. 857.

Liu L., Zhang Y., Liu G. et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients // J. Hypertens. — 2005. — Vol. 23. —

P. 2157-2172.

Loaldi A., Polese A., Montorsi P. et al. Nifedipine prevents the progression of coronary atherosclerosis // InPharma. — 1989. — Vol. 705. — P. 13.

Lüscher T.F., Pieper M., Tendera M. et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study // Eur. Heart J. — 2009. — Vol. 30. — P. 1590-1597.

Ma G., Allen T., Cooper M. et al. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes // Kidney Int. — 2004. — Vol. 66(3). — P. 1090-1098.

Martın-Ventura J., Munoz-Garcia B., Blanco-Colio L. et al. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis // Kidney International. — 2008. — Vol. 111. — P. S71-S74.

Marx A., Lichtenthal A., Milbredt C. et al. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases // J. Hypertens. — 2004. — Vol. 22, Suppl. 2. — S236.

Mason R.P., Walter M.F., Day C.A., Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions // Am. J. Cardiol. — 2005. — Vol. 96(5A). — P. 11F-23F.

Mason R.P. A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence // Curr. Drug. Targets Cardiovasc. Haematol. Disord. — 2005. — Vol. 5(6). — P. 489-501.

MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results // BMJ. — 1992. — Vol. 304(6824). — P. 405-412.

Messerli F.H., Bakris G.L., Ferrera D. et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial // J. Clin. Hypertens. (Greenwich). — 2006. — Vol. 8(8). — P. 571-581.

Mourad J.J., Waeber B., Zannad F. et al. Investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach // J. Hypertens. — 2004. — № 22. — 2379-2386.

Nakamura M., Sato K., Nagano M. Estimation of aortic systolic blood pressure in community-based screening: the relationship between clinical characteristics and peripheral to central blood pressure differences // J. Hum. Hypertens. — 2005. — Vol. 19. — P. 251-253.

National Center for Health Statistics. — Feb 24, 2008. — Accessed on Jan 10, 2009. — Available from:

Nissen S.E., Tuzcu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial // JAMA. — 2004. — Vol. 292. — P. 2217-2225.

Nomura S., Inami N., Kimura Y. et al. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus // J. Hum. Hypertens. — 2007. — Vol. 21(1). — P. 38-44.

Packer M., O’Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group // N. Engl. J. — 1996. — Vol. 335. — P. 1107-1114.

Pearson T.A., Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals // Arch. Intern. Med. — 2000. — Vol. 160(4). — P. 459-467.

Pedersen T.R., Faergeman O., Kastelein J.J. et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial // JAMA. — 2005. — Vol. 294(19). — P. 2437-2445.

Pettitt D., Karter A.J., Peng T.Y. et al. The impact of concurrent dyslipidemia and diabetes on hypertension management and goal attainment. Vancouver, Canada: Poster presentation at the 26th Annual Meeting of the Society of General Internal Medicine; 2003.

Pitt B., Byington R., Furberg C. et al. Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events // Circulation. — 2000. — Vol. 102. — P. 1503-1510.

Pontremoli R., Leoncini G., Parodi A. Use of nifedipine in the treatment of hypertension // Expert Rev. Cardiovasc. Ther. — 2005. — Vol. 3. — P. 43-50.

Poulter N.R., Chang C.L., Dahlöf B. et al. Evaluating the efficacy of the stepped-care anti-hypertensive strategies used in the Anglo-Scandinavian Cardiac Outcomes Trial BP Lowering Arm

(ASCOT) [abstract no. OS11/1] // J. Hypertens. — 2008. — Vol. 26, Suppl. 1. — P. S10.

Preston R.A., Harvey P., Herfert O. et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial // J. Clin. Pharmacol. — 2007. — Vol. 47(12). — P. 1555-1569.

Preston R.A., Harvey P., Herfert O. et al. Reduction in Framingham cardiovascular risk with concomitant treatment of hypertension/dyslipidemia with amlodipine/atorvastatin // Am. J. Hypertens. — 2005. — Vol. 18. — P. A226.

Preston R.A., Sun F., Tarasenko L. Safety and tolerability of coadministered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the Respond study // Am.

J. Hypertens. — 2005. — Vol. 18. — P. A92-A93.

Rahman M., Pressel S., Davis B.R. et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Arch. Intern. Med. — 2005. — Vol. 165(8). — P. 936-946.

Robles N.R., Ocon J., Gomez Campder F. et al. Lercanidipine in chronic renal failure patients: The ZAFRA Study // Ren. Fail. — 2005. — Vol. 27. — P. 73-80.

Schroeder K., Fahey T., Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Sytematic review of randomized controlled trials // Arch. Intern. Med. — 2004. — Vol. 164(7). — P. 722-732.

Sever P.S., Dahlöf B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial // Lancet. — 2003. — Vol. 361. — P. 1149-1158.

Sharman J.E., Stowasser M., Fassett R.G., Marwick T.H., Franklin S.S. Central blood pressure measurement may improve risk stratification // J. Hum. Hypertens. — 2008. — Vol. 22. — P. 838-844.

SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) // JAMA. — 1991. — Vol. 265. — P. 3255-3264.

Shepherd J., Barter P., Carmena R. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study // Diabetes Care. — 2006. — Vol. 29(6). — P. 1220-1226.

Simon A., Levenson J. Clinical use of nifedipine GITS in the treatment of hypertension: an overview // Expert Opin. Pharmacother. — 2003. — Vol. 4(1). — P. 95-106.

Smith T.W.C.S., Tang S.S.K. et al. Clinical and economic consequences of single pill combination of amlodipine/atorvastatin compared with a two-pill regimen in hypertension patients with additional cardiovascular risk factors // Eur. Heart J. — 2007. — Vol. 28 (Abstr. Suppl.). — P. 857.

Staessen J., Fagard R., Thijs L. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension // Lancet. — 1997. — Vol. 350. — P. 757-764.

Stroke Prevention by Aggressive Reduction in Cholesterol Levels The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack // N. Engl. J. Med. — 2006. — Vol. 355. — P. 549-559.

Taddei S., Ghiadoni L., Salvetti A. Current treatment of patients with hypertension: therapeutic implications of INSIGHT // Drugs. — 2003. — Vol. 63(14). — P. 1435-44.

Wald D., Law M., Morris J. et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials // Am. J. Med. — 2009. —

Vol. 122. — P. 290-300.

Wald D.S., Morris J.K., Wald N.J. Randomized Polypill Crossover Trial in People Aged 50 and Over // PLoS ONE. — 2012. — 7(7). — e41297. doi:10.1371/journal.pone.0041297

Wang J.G., Staessen J.A., Gong L., Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group // Arch. Intern. Med. — 2000. — Vol. 160(2). — P. 211-20.

Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical values in the VALUE trial // Lancet. — 2004. — Vol. 363. — P. 2047-2049.

Wenzel R.R. Renal protection in hypertensive patients: selection of antihypertensive therapy // Drugs. — 2005. — Vol. 65,

Suppl. 2. — P. 29-39.

Wide-Swensson D.H., Ingemarsson I., Lunell N.O. et al. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study // American journal of obstetrics and gynecology. — 1995. — Vol. 173 (3 Pt. 1). — P. 872-878.

Wilkinson I., Franklin S., Hall I. et al. Pressure Amplification Explains Why Pulse Pressure is unrelated to risk in young subjects // Hypertens. — 2001. — Vol. 38. — P. 1461-1466.

Wing L.M., Reid C.M., Ryan P., Beilin L.J., Brown M.A., Jennings G.L. et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly // N. Engl. J. Med. — 2003. — Vol. 348. — P. 583-592.

Zancetti A., Bond G., Henning M. et al. On behalf of ELSA investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial // Circulation. — 2002. — Vol. 106. — P. 2422-2427.

Zucchelli P., Zuccalà A., Borghi M. et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency // Kidney Int. — 1992. — Vol. 42(2). —

P. 452-458.

Murphy S.A., Cannon C.P., Wiviott S.D., McCabe C.H., Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial // J. Am. Coll. Cardiol. — 2009. — Vol. 54. — P. 2358-2362.

Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial // JAMA. — 2004. — Vol. 291(9). — P. 1071-1080.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта